40,919 Shares in BioMarin Pharmaceutical Inc. $BMRN Bought by Paralel Advisors LLC

Key Points

• Paralel Advisors acquired 40,919 BioMarin shares in the second quarter, valued at approximately $2.34 million. Institutional investors collectively own 98.71% of BMRN’s outstanding shares.
• Analyst sentiment is broadly positive but mixed, with the stock receiving a “Moderate Buy” consensus rating and an average price target of $88.83. Recent upgrades from Citigroup and Morgan Stanley contrast with a sell rating from Weiss Ratings.
• BioMarin exceeded quarterly expectations, reporting $1.20 in earnings per share and $989.7 million in revenue, with revenue up 20% year over year. Shares opened at $67.68, near the company’s 12-month high of $70.98.

Paralel Advisors LLC acquired a new position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 40,919 shares of the biotechnology company's stock, valued at approximately $2,341,000.

Other hedge funds have also recently made changes to their positions in the company. Rice Hall James & Associates LLC purchased a new stake in BioMarin Pharmaceutical during the second quarter valued at approximately $14,203,000. Swedbank AB boosted its holdings in shares of BioMarin Pharmaceutical by 70.6% in the 4th quarter. Swedbank AB now owns 796,737 shares of the biotechnology company's stock worth $47,350,000 after purchasing an additional 329,794 shares during the period. LSV Asset Management boosted its holdings in shares of BioMarin Pharmaceutical by 4.3% in the 4th quarter. LSV Asset Management now owns 882,200 shares of the biotechnology company's stock worth $52,429,000 after purchasing an additional 36,700 shares during the period. C WorldWide Group Holding A S increased its position in shares of BioMarin Pharmaceutical by 12.6% during the 4th quarter. C WorldWide Group Holding A S now owns 267,851 shares of the biotechnology company's stock valued at $15,918,000 after purchasing an additional 30,000 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new position in shares of BioMarin Pharmaceutical during the 2nd quarter valued at approximately $944,000. 98.71% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

BMRN has been the subject of a number of analyst reports. Citigroup raised their price target on BioMarin Pharmaceutical from $75.00 to $76.00 and gave the stock a "buy" rating in a research report on Thursday, July 16th. Wall Street Zen upgraded shares of BioMarin Pharmaceutical from a "hold" rating to a "buy" rating in a research report on Saturday, August 8th. Weiss Ratings cut shares of BioMarin Pharmaceutical from a "hold (c-)" rating to a "sell (d)" rating in a research report on Tuesday, August 11th. Morgan Stanley increased their target price on shares of BioMarin Pharmaceutical from $119.00 to $124.00 and gave the company an "overweight" rating in a research note on Friday, August 7th. Finally, The Goldman Sachs Group began coverage on shares of BioMarin Pharmaceutical in a report on Monday, May 11th. They issued a "neutral" rating and a $69.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $88.83.

Trending Headlines about BioMarin Pharmaceutical

Here are the key news stories impacting BioMarin Pharmaceutical this week:

• Positive Sentiment: BMO upgrades BioMarin to “strong buy.” The upgrade follows BMO’s recent initiation of coverage with an “outperform” rating and a $98 price target, implying substantial upside from the current trading level. BMO upgrades BioMarin to strong buy
• Positive Sentiment: Alesta acquisition expands BioMarin’s rare-disease pipeline. BioMarin agreed to acquire Alesta Therapeutics for $275 million upfront, with up to $215 million in milestone payments. The deal adds ALE1, an oral treatment candidate for hypophosphatasia, a rare genetic bone disorder, and could strengthen the company’s long-term growth prospects if development and regulatory milestones are achieved. BioMarin Alesta acquisition
• Positive Sentiment: Recent operating results were stronger than expected. BioMarin’s latest reported quarter exceeded consensus earnings and revenue estimates, with revenue increasing 20% year over year. Articles from Barclays and Piper Sandler also point to potential share-price appreciation. BioMarin Q2 results benchmarking
• Neutral Sentiment: The Alesta opportunity remains early stage. ALE1 is still in clinical development, meaning the potential commercial benefit is several years away and depends on successful trials, approvals and milestone execution. The transaction therefore adds strategic potential but also development risk. BioMarin to acquire Alesta
• Negative Sentiment: Analyst opinion is not unanimous. HC Wainwright issued a pessimistic forecast, while another analyst reduced the price target to $59 despite viewing the Alesta deal favorably. This valuation disagreement may limit near-term upside and contribute to selling pressure. BioMarin analyst price target cut

BioMarin Pharmaceutical Stock Performance

BMRN stock opened at $67.68 on Friday. The company has a quick ratio of 1.32, a current ratio of 2.39 and a debt-to-equity ratio of 0.56. The business's fifty day simple moving average is $60.45 and its two-hundred day simple moving average is $57.82. BioMarin Pharmaceutical Inc. has a twelve month low of $49.26 and a twelve month high of $70.98. The firm has a market cap of $13.10 billion, a price-to-earnings ratio of 182.92, a PEG ratio of 0.50 and a beta of 0.24.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last released its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.25. The business had revenue of $989.71 million during the quarter, compared to the consensus estimate of $932.03 million. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%.The business's revenue for the quarter was up 20.0% compared to the same quarter last year. During the same period last year, the company earned $1.44 earnings per share. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Analysts predict that BioMarin Pharmaceutical Inc. will post 4.11 earnings per share for the current year.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company's commercial portfolio includes several approved therapies targeting inherited disorders.

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source